Navigation Links
LSUSHC research identifies new experimental drug for stroke
Date:2/29/2012

New Orleans, LA Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke. Dr. Bazan was issued a patent on the molecule called LAU-0901, a low molecular weight drug that crosses the blood-brain barrier. The findings are published in the March 2012 issue of Translational Stroke Research.

During an ischemic stroke, the most common kind, the body releases signals that cause neuroinflammation which leads to a buildup of chemicals that harm the brain. Platelet-activating factor (PAF) accumulates, and inhibition of this process plays a critical role in neuronal survival.

"LAU-0901 is able to reduce this incorrect signaling and inhibit the PAF receptor, which reduces multiple neuroinflammatory signals and greatly lessens the severity of damage in experimental stroke," notes Dr. Bazan.

The research team used magnetic resonance imaging in conjunction with behavior and immunohistopathology to further study this novel therapeutic approach. The researchers report that LAU-0901, given two hours after the onset of experimental stroke, lessened the severity of brain damage, significantly reduced lesions in the brain, and improved coordination and movement. LAU-0901 produced no discernible side effects. These findings suggest LAU-0901 is a promising neuroprotectant that provides the basis for future therapeutics in patients suffering ischemic stroke.

Stroke is a leading cause of death and disability worldwide. Conventional therapies for ischemic stroke include thrombolytic therapy, prevention of inappropriate coagulation and thrombosis, and surgery to repair vascular abnormalities.Only one FDA-approved therapy exists for treatment of acute ischemic stroke, the thrombolytic tissue plasminogen activator (tPA), but only 5𔃆% of all ischemic stro
'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. LSUSHC researchers find potential new target for hypertension treatment
2. Wistar Institute researcher receives New Innovator award from NIH
3. NC State researchers get to root of parasite genome
4. White Mountain Research Station to host climate change conference
5. Stevens awarded $1M for advanced biofuels research
6. Researchers find animal with ability to survive climate change
7. Researchers find an essential gene for forming ears of corn
8. Researchers note differences between people and animals on calorie restriction
9. Researcher working on destruction of chemical weapons
10. Researchers study acoustic communication in deep-sea fish
11. Researchers discover that growing up too fast may mean dying young in honey bees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/6/2015)... 6, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, ... 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND ... NXT-ID introduces a new revolutionary method and ... the use of miniature antenna modules for multiple ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... team of neuroengineers based at Brown University has developed ... of relaying real-time broadband signals from up to 100 ... novel low-power device, described in the Journal of ... models for more than year, a first in the ...
... long-term consequences of childhood obesity are well documented, some ... more time to the 3 Rs in educationreading, writing, ... leaving out an important fourth Raerobicscould actually be counterproductive ... for publication in The Journal of Pediatrics ...
... at Wake Forest Baptist Medical Center and colleagues have ... bone marrow that have the natural ability to migrate ... potential to restore healthy tissue in patients with inflammatory ... have IBD, which is characterized by frequent diarrhea and ...
Cached Biology News:Brown unveils novel wireless brain sensor 2Brown unveils novel wireless brain sensor 3Brown unveils novel wireless brain sensor 4Reading, writing, arithmetic, and aerobics -- Evaluating the new 'R' in academic performance 2Research supports promise of cell therapy for bowel disease 2
(Date:4/24/2015)... N.J. , April 24, 2015  Navitas Life Sciences ... as Head of Clinical and Regulatory Services. Shalabh is ... been a co-founder and CEO of Kinapse, as well as ... Logo - http://photos.prnewswire.com/prnh/20150423/201261LOGO ... Jim Tizzard commented "I am delighted to welcome Shalabh ...
(Date:4/23/2015)... 23, 2015 The Thomas Brain ... conduct a groundbreaking pilot study to see if ... in as little as three to six months. ... and nutritional medicine—will aggressively target and simultaneously treat ... our aging brain. These include oxidative stress, neuroinflammation, ...
(Date:4/23/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company serving the pharmaceutical, biotechnology and medical device industries, ... the United States , today announced ... quarter of 2015 after the New York Stock Exchange ... Thursday morning, May 14, 2015 Shanghai time). The earnings ...
(Date:4/23/2015)... April 23, 2015 Glemser ... the first EMC® Enterprise Content Division (ECD) Certified ... EMC Documentum® for Life Sciences Solution Suite ... knowledge and capabilities to provide life sciences companies ... , The EMC Documentum Solution Suite offers ...
Breaking Biology Technology:Shalabh Kumar Joins Navitas Life Sciences to Lead their Clinical and Regulatory Services Teams 2New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... of HER1, HER2 and HER3 Assays to Provide Unique ... Facilitate Development of Personalized Cancer Therapies, SOUTH SAN ... ) today announced that the company,s HER1,and HER3 Quantitative ... on Monogram,s VeraTag(TM) platform, the HER1 and,HER3 assays provide ...
... Meeting of Shareholders to be Reconvened on May 29, ... Therapeutics,Corporation (Nasdaq: UTHR ) (the Company) held its ... 2008. The Company,s,shareholders voted to approve the election of ... directors with terms expiring in 2011. The,Company,s shareholders also ...
... IRVINE, Calif., May 1 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, will host ... 2008 beginning at 10:00 a.m. PT (1:00 pm,ET) ... A live webcast of the meeting will be ...
Cached Biology Technology:HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 2HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 3HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 4HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics 5United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 2United Therapeutics Announces the Results of Its 2008 Annual Meeting of Shareholders 3Edwards Lifesciences to Webcast Annual Stockholders Meeting 2
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Recognizes rat Taste Receptor 2 (TR2). The immunogen shows no significant sequence homology with TR1, gustducin or other pheromone receptors....
Rat monoclonal [HK5.3] to B7 RP1 (Biotin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: